Company: BDRX
Filing Date: 2025-05-12
Form Type: 424B3
Source: 0001214659-25-007340
Chunk: 16

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-12
Form: 424B3
Chunk 16
---
,400 Ordinary Shares represented by 1,939 Depositary Shares, issuable upon the exercise of Series B warrants, or Series B Warrants, issued in the February Private Placement at an exercise price of $5,536.00 per warrant, and (4) 62,184,525 Ordinary Shares represented by 6,218 Depositary Shares, issuable upon the exercise of pre-funded warrants issued in the February Private Placement at an exercise price of $0.80 per warrant, for aggregate gross proceeds of approximately $6.0 million. We also issued unregistered warrants to the placement agent in the offering, or the February Placement Agent Warrants, to purchase a total of 536,800 Ordinary Shares represented by 52 Depositary Shares to the placement agent at an exercise price of $10,000.00 per warrant for one warrant and an exercise price of $5,800.00 per warrant for 51 warrants, and Series A Warrants to purchase 625,000 Ordinary Shares represented by 62 Depositary Shares at an exercise price of $5,360.00 per warrant to an investor pursuant to a waiver.

On
March 27, 2023, following shareholder approval, we effected a one-for-20 reverse split of our ordinary shares, and our ordinary shares
began trading on AIM on a split-adjusted basis as of such date. No fractional shares were issued in connection with the reverse stock
split.

Concurrently
with the reverse split, and in an effort to bring the Depositary Shares price into compliance with NASDAQ’s minimum requirement
for 500,000 listed Depositary Shares, on March 27, 2023, we effected a ratio change in the number of our ordinary shares represented by
the Depositary Shares from 25 ordinary shares per Depositary Share to five ordinary shares per Depositary Share. No fractional Depositary
Shares were issued.

Between
March 27, 2023 and December 31, 2024, we have issued 95,137,075 Ordinary Shares upon the exercise of pre-funded warrants, Series A Warrants
and Series B Warrants issued in the February Private Placement.

On
May 26, 2023, we completed the closing of a registered direct offering with institutional investors of (1) 166,017,700 Ordinary Shares
represented by 16,601 Depositary Shares, issuable upon the exercise of the Series C warrants, or Series C Warrants, at an exercise price
of $400.00